hydroxyurea + vincristine + triazinate

**Hydroxyurea + vincristine + triazinate** is a combination chemotherapy regimen consisting of hydroxyurea (a ribonucleotide reductase inhibitor that depletes deoxyribonucleotide pools to block DNA synthesis), vincristine (a vinca alkaloid that binds tubulin to inhibit microtubule formation and mitotic spindle assembly), and triazinate (a synthetic dihydrotriazine antifolate that inhibits dihydrofolate reductase to disrupt folate metabolism and DNA/RNA synthesis). This triplet targets rapidly proliferating cancer cells through complementary antimetabolite and antimitotic mechanisms, historically evaluated in preclinical and early clinical settings for advanced solid tumors, though no unique brand name or large-scale trials define it as a standardized regimen. Primary indications appear investigational for cancers responsive to antifolates and myelosuppressives, such as colorectal, gastric, or renal carcinomas, with administration typically intravenous for vincristine and oral for others.